A comparison of the pattern of Cathepsin-D expression in fibroadenoma, fibrocystic disease, preinvasive and invasive ductal breast carcinoma

Pathology

Volumn 31, Issue 3, 1999, Pages 247-251

  Zheng, Wei Qiang ^a   Looi, Lai Meng ^b   Cheah, Phaik Leng ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Breast; Carcinoma; Cathepsin D; Immunohistochemistry; Metastasis

Indexed keywords

CATHEPSIN D;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; BREAST DISEASE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CARCINOMA IN SITU; FEMALE; FIBROADENOMA; FIBROCYSTIC BREAST DISEASE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MYOEPITHELIUM CELL; RETROSPECTIVE STUDY; STROMA CELL; TUMOR VOLUME;

EID: 0032868272     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/003130299105061     Document Type: Article

References (35)

1. Mullins DE, Rohrlich ST. The role of proteinases in cellular invasiveness. Biochim Biophys Acta 1983; 695: 177-214.
2. Rochefort H, Capony F, Garcia M. Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev 1990; 9: 321-31.
3. Westley B, Rochefort H. Estradiol induced proteins in the MCF-7 human breast cancer cell line. Biophys Res Commun 1979; 90: 410-6.
4. Vignon F, Capony F, Chambon M, et al. Autocrine growth stimulation of the MCF-7 breast cancer cells by the estrogen-regulated 52k protein. Endocrinology 1986; 118: 1537-45.
5. Takei Y, Higashira H, Yamamoto T, Hayashi K. Mitogenic activity toward human breast cancer cell line MCF-7 of two bFGFs purified from sera of breast cancer patients: co-operative role of cathepsin D. Breast Cancer Res Treat 1997; 43: 53-63.
6. Westley B, May FEB, Brown AMC, et al. Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF-7 cells and two tamoxifen-resistant sublines. J Biol Chem 1984; 259: 10030-5.
7. Capony F, Rougeot C, Montcourrier P, et al. Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cells. Cancer Res 1989; 49: 3904-9.
8. Rochefort H, Capony F, Garcia M. Cathepsin D in breast cancer: from molecular and cellular biology to clinical applications. Cancer Cells 1990; 2: 383-8.
9. Faust PL, Kornfeld S, Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acatl Sci USA 1985; 82: 186-92.
10. Augereau P, Garcia M, Mattei MG, et al. Cloning and sequencing of the 52 kD cathepsin D implementary deoxyribonucleic acid of MCF-R breast cancer cells and mapping on chromosome 11. Mol Endocrinol 1988; 2: 186-92.
11. Rochefort H. Biologial and clinical significance of cathepsin D in breast cancer. Semin Cancer Biol 1990; 1: 153-60.
12. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. New Engl J Med 1990; 322: 297-302.
13. Fulco RA, Petrix M, Salimbeni V, Torre EA. Prognostic significance of the estrogen-regulated proteins, cathepsin-D and pS2, in breast cancer. Minerva Med 1998; 89: 5-10.
14. Kute TE, Shao ZM, Sugg NK, et al. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992; 52: 5198-203.
15. Barbi GP, Margallo E, Margiocco M, et al. Evaluation of cathepsin D as prognostic predictor in breast cancer. Oncology 1994; 51: 329-33.
16. Pujol P, Maudelonde T, Daures JP, et al. A propective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993; 71: 2006-12.
17. Razumovic JJ, Stojkovic RR, Petrovecki M, Gamulin S. Correlation of two methods for determination of cathepsin D in breast carcinoma (immunohistochemistry and ELISA in cytosol). Breast Cancer Res Treat 1997; 43: 117-22.
18. Remmele W, Sauer-Manthey J. Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer, Virchows Arch A Pathol 1993; 422: 467-73.
19. Winstanley JH, Leinster SJ, Cooke TO, et al. Prognostic significance of cathepsin D in patients with breast cancer. Br J Cancer 1993; 67: 767-72.
20. Isola J, Weitz S, Visakorpi T, et al. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993; 11: 36-43.
21. Charpin C, Devictor B, Bonnier P, et al. Cathepsin D immunocytochemical assays in breast carcinomas: Image analysis and correlation to prognostic factors. J Pathol 1993; 170: 463-70.
22. Castiglioni T, Merino MJ, Elsner B, et al. Immunohistochemical analysis of cathepsins D, B and L in human breast cancer. Hum Pathol 1994; 25: 847-8.
23. Joensuu H, Toikkanen S, Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 1995; 71: 155-9.
24. Tetu B, Brisson J, Cote C, et al. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993; 55: 429-35.
25. O'Donoghue AE, Poller DN, Bell JA, et al. Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat 1995; 33: 137-45.
26. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987; 300-11.
27. Bolufer P, Torregrosa MD, Gomez L, et al. Specific oncological contribution of cathepsin D and pS2 in human breast cancer: their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification, Clin Chim Acta 1996; 247: 89-103.
28. Briozzo P, Badet J, Capony F, et al. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 1991; 194: 252-9.
29. Johnson MD, Toni JA, Lippman ME, Dickson RB. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 1993; 53: 873-7.
30. Ioachim E, Kamina S, Kontostolis M, Agnantis NJ. Immunohistochemical expression of cathepsin D in correlation with extracellular matrix component, steroid receptor status and proliferative indices in breast cancer. Virchows Arch 1997; 431: 311-6.
31. Nadji M, Fresno M, Nassiri M, et al. Cathepsin D in host stromal cells but not in tumor cells, is associated with aggressive behaviour in node-negative breast cancer. Hum Pathol 1996; 27: 890-5.
32. Losch A, Tempfer C, Kohlberger P, et al. Prognostic value of cathepsin D expression and association with histomorphological subtypes in breast cancer. Br J Cancer 1998; 78: 205-9.
33. Harbeck N, Dettmar P, Thomssen C, et al. Prognostic impact of tumour biological factors on survival in node-negative breast cancer. Anticancer Res 1998; 18: 2187-97.
34. Nikolic-Vukosavljevic D, Grujic-Adanja G, Nastic-Miric D, et al. Cathepsin D: association between TN-stage and steroid receptor status of breast carcinoma. Tumour Biol 1998; 19: 329-34.
35. Gohring UJ, Scharl A, Thelen U, et al. Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods. J Clin Pathol 1996; 49: 57-64.